Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) were up 10.4% during trading on Monday . The company traded as high as $3.93 and last traded at $3.99. Approximately 649,644 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 1,283,485 shares. The stock had previously closed at $3.61.
Analyst Ratings Changes
A number of analysts have recently issued reports on SVRA shares. Oppenheimer boosted their price objective on Savara from $6.00 to $8.00 and gave the company an "outperform" rating in a research report on Monday, September 8th. Lifesci Capital raised shares of Savara to a "strong-buy" rating in a report on Tuesday, October 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research note on Wednesday, October 8th. Guggenheim lifted their target price on shares of Savara from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, September 9th. Finally, Wells Fargo & Company started coverage on shares of Savara in a research note on Monday. They issued an "overweight" rating and a $7.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $7.50.
View Our Latest Report on SVRA
Savara Price Performance
The company's 50 day moving average price is $3.39 and its 200 day moving average price is $2.89. The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The company has a market cap of $710.37 million, a price-to-earnings ratio of -8.22 and a beta of 0.46.
Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). On average, equities research analysts predict that Savara Inc. will post -0.45 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Savara
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Prudential Financial Inc. bought a new position in shares of Savara in the second quarter valued at about $30,000. BNP Paribas Financial Markets increased its position in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after acquiring an additional 4,626 shares in the last quarter. May Hill Capital LLC bought a new position in shares of Savara in the second quarter worth about $32,000. Brevan Howard Capital Management LP bought a new stake in shares of Savara during the second quarter valued at approximately $33,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Savara during the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 87.93% of the company's stock.
Savara Company Profile
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
